Analysts Set Vericel Co. (NASDAQ:VCEL) Target Price at $46.80

Vericel Co. (NASDAQ:VCELGet Free Report) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $46.80.

VCEL has been the topic of a number of analyst reports. StockNews.com lowered shares of Vericel from a “hold” rating to a “sell” rating in a report on Monday. Truist Financial reaffirmed a “buy” rating and set a $54.00 price objective on shares of Vericel in a research report on Tuesday, March 26th. Finally, HC Wainwright raised their target price on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th.

Get Our Latest Research Report on Vericel

Insiders Place Their Bets

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now directly owns 195,307 shares of the company’s stock, valued at approximately $8,708,739.13. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now owns 195,307 shares of the company’s stock, valued at $8,708,739.13. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Sean C. Flynn sold 8,115 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $45.33, for a total value of $367,852.95. Following the transaction, the senior vice president now directly owns 167 shares of the company’s stock, valued at $7,570.11. The disclosure for this sale can be found here. Insiders sold a total of 54,267 shares of company stock worth $2,450,996 in the last 90 days. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vericel

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Congress Asset Management Co. MA grew its stake in Vericel by 509.1% during the 1st quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after acquiring an additional 699,147 shares in the last quarter. William Blair Investment Management LLC increased its position in Vericel by 59.5% during the third quarter. William Blair Investment Management LLC now owns 855,207 shares of the biotechnology company’s stock worth $28,667,000 after acquiring an additional 318,916 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Vericel during the first quarter valued at about $12,782,000. Comerica Bank lifted its position in shares of Vericel by 61,063.9% in the 3rd quarter. Comerica Bank now owns 208,569 shares of the biotechnology company’s stock worth $6,991,000 after acquiring an additional 208,228 shares during the period. Finally, Geneva Capital Management LLC boosted its stake in Vericel by 43.6% during the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock worth $35,330,000 after buying an additional 206,202 shares in the last quarter.

Vericel Trading Up 3.1 %

Shares of VCEL opened at $48.18 on Tuesday. The firm has a market cap of $2.34 billion, a P/E ratio of -4,813.19 and a beta of 1.74. Vericel has a 12 month low of $30.18 and a 12 month high of $53.05. The stock’s 50 day moving average is $48.45 and its two-hundred day moving average is $43.11.

Vericel (NASDAQ:VCELGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The firm had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. During the same period last year, the company posted ($0.16) EPS. Vericel’s quarterly revenue was up 25.0% compared to the same quarter last year. Equities research analysts forecast that Vericel will post 0.1 EPS for the current year.

About Vericel

(Get Free Report

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

See Also

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.